Eli Lilly Threatens to Cut 340B Discounts for Hospitals Refusing Data Sharing
Eli Lilly has issued an ultimatum to certain 340B hospitals requiring them to share data proving they are not duplicating drug discounts by Monday or face loss of 340B pricing. The pharmaceutical company claims some hospitals refuse to provide documentation showing compliance with program requirements prohibiting duplicate Medicaid and 340B discounts on the same claim. Hospitals are pushing back and requesting federal government intervention. The dispute centers on manufacturer attempts to limit 340B discounts amid concerns about program integrity and duplicate discounting.
Medicaid managed care organizations could face pharmacy cost increases if 340B hospital access to discounted drugs is restricted, potentially affecting drug rebate calculations and contract pharmacy arrangements with safety-net providers.
Pharmacy · Managed Care
You might also like